@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix go: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix hasAgent: . @prefix sfam: . @prefix species: . @prefix occursIn: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 hasAgent: sub:_2; a go:0016301 . sub:_2 geneProductOf: hgnc:9829; a Protein: . sub:_3 hasAgent: sub:_4; a go:0016301 . sub:_4 geneProductOf: sfam:MAPK%20Erk1%2F2%20Family; a Protein: . sub:_5 occursIn: species:9606; rdf:object sub:_3; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "kin(p(HGNC:RAF1)) -> kin(p(SFAM:\"MAPK Erk1/2 Family\"))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_7; pav:version "20131211" . sub:_6 prov:value "3CH134 protein, and the protein synthesis inhibitor cycloheximide leads to persistent activation of MAP kinase. 3CH134 blocks phosphorylation and activation of p42MAPK mediated by serum, oncogenic Ras, or activated Raf"; prov:wasQuotedFrom pubmed:8221888 . sub:_7 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:8221888; prov:wasDerivedFrom beldoc:, sub:_6 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:49.611+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }